Phase I studies of TVB-2640, the first FASN inhibitor to enter clinical trials for prostate cancer, indicated a favorable tolerability profile as either monotherapy or in combination with taxane in four heavily pre-treated prostate cancer patients (144). This evidence concerns the gene FASN and prostate cancer.